Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 Substudy 04A: Investigational Agents With or Without Pembrolizumab in PD-1/L1 Refractory Urothelial Carcinoma
NCT05562830Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Primary completion
- Feb 2029
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of zilovertamab vedotin, MK-3120 in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Nov 2022; status: recruiting.
02
Drugs
zilovertamab vedotinMK-3120
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05562830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562830.